Bioavailability and acceptability of a dispersible formulation of levodopa-benserazide in parkinsonian patients with and without dysphagia

Bayer, Antony James ORCID: https://orcid.org/0000-0002-7514-248X, Day, J. J., Finucane, P. and Pathy, M. S. J. 1988. Bioavailability and acceptability of a dispersible formulation of levodopa-benserazide in parkinsonian patients with and without dysphagia. Journal of Clinical Pharmacy and Therapeutics 13 (3) , pp. 191-194. 10.1111/j.1365-2710.1988.tb00179.x

Full text not available from this repository.

Abstract

The bioavailability of levodopa-benserazide in a standard capsule and a new dispersible tablet was compared in Parkinsonian patients, with (n = 8) and without (n = 8) swallowing difficulties. There was considerable variation within and between subjects, but no significant differences between formulations for any pharmacokinetic parameters, other than an earlier timepeak concentration following the dispersible tablets (P < 0.01) in non-dysphagic patients. The acceptability of the dispersible tablets in the dysphagic patients was also determined following 7 days regular use. It was felt there were advantages in four of the patients because it was easier to administer or to swallow. The dispersible formulation may offer practical benefits to a minority of Parkinsonian patients without any anticipated loss of therapeutic efficacy.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > RM Therapeutics. Pharmacology
Publisher:	Wiley-Blackwell
ISSN:	0269-4727
Last Modified:	24 Oct 2022 12:00
URI:	https://orca.cardiff.ac.uk/id/eprint/50058

Citation Data

Cited 23 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item